In accordance with Joint Accreditation criteria and the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, the Association of Diabetes Care & Education Specialists (ADCES) must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial
relationships with any ineligible companies for the past 24 months.
Joint Accreditation/ACCME also requires that ADCES mitigate any reported conflict and eliminate the potential for bias during the educational activity. The disclosure information is intended to identify any ineligible relationships and allow learners to form their own judgments. However, if you perceive a bias during an activity, please report it on the evaluation.
Relevant disclosures (or lack thereof) among educational activity planners and faculty are as follows:
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP - Speakers Bureau: Dexcom, Insulet, Medtronic, Abbott, Novo Nordisk, Bayer, Xeris Pharmaceuticals; Consultant: Lilly, Sanofi, Tempramed, DiabetesWise, DiaTribe
Marisa Hilliard, Ph.D. – No conflicts of interest
Jodi Lavin-Tompkins, MSN, RN, CDCES, BC-ADM – Stock: Gilead Sciences, Regeneron Pharma
Disclosure and Mitigation of Relevant Conflicts of Interest
All identified relevant conflicts of interest have been mitigated.
The approval of this educational offering by the ADCES does not imply endorsement of specific therapies, treatments, or products discussed in the presentations.